Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Top Cited Papers
- 25 October 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 18 (12), 1319-1328
- https://doi.org/10.1016/s1473-3099(18)30554-1
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Global dissemination of extensively drug‐resistant carbapenemase‐producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection controlJournal of Internal Medicine, 2015
- Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter speciesClinical Microbiology & Infection, 2014
- Deaths Attributable to Carbapenem-ResistantEnterobacteriaceaeInfectionsEmerging Infectious Diseases, 2014
- Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemasesThe Lancet Infectious Diseases, 2013
- Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile InfectionAntimicrobial Agents and Chemotherapy, 2013
- Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized studyCurrent Medical Research and Opinion, 2012
- Stenotrophomonas maltophilia: an Emerging Global Opportunistic PathogenClinical Microbiology Reviews, 2012
- Current Epidemiology and Growing Resistance of Gram-Negative PathogensThe Korean Journal of Internal Medicine, 2012
- Carbapenem-Resistant Enterobacteriaceae: Epidemiology and PreventionClinical Infectious Diseases, 2011
- The ferric yersiniabactin uptake receptor FyuA is required for efficient biofilm formation by urinary tract infectious Escherichia coli in human urineMicrobiology, 2008